menu search

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
– Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in the second quarter – – Dr. Anne Borgman joined Sutro as Chief Medical Officer in February 2023 – – Sutro expanded its relationship with Vaxcyte through an option agreement for the development and manufacturing rights […] The post Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones appeared first on ForexTV... Read More
Posted: Mar 30 2023, 20:30
Author Name: forextv
Views: 101993

Search within

Pages Search Results: